BUZZ-Ovid Therapeutics rises as epilepsy drug shows clean safety

Reuters03-18
BUZZ-Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises as epilepsy drug shows clean safety

** Shares of biotech firm Ovid Therapeutics OVID.O rise about 16% to $2.33 premarket

** Says experimental epilepsy drug OV329 showed a clean safety profile in an early-stage study

** Volunteers given a 7 mg dose reported no treatment-related side effects; other events were mild and short-lived - OVID

** Says no signs of eye problems, a known risk with older drugs in the same class

** Plans a mid-stage trial in focal onset seizures, a common form of epilepsy, in Q2

** Also plans studies in rare childhood seizure disorders, including tuberous sclerosis complex and infantile spasms

** Raises $60 mln in a private funding round to support the studies

** Shares gained ~75% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment